CCM
MIRM icon

Cadian Capital Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Cadian Capital Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-475,714
Closed -$18.6M – 31
2024
Q3 		$18.6M Sell
475,714
-759,407
-61% -$30.3M 0.95% 26
2024
Q2 		$42.2M Sell
1,235,121
-1,057,446
-46% -$27.7M 2.1% 17
2024
Q1 		$57.6M Buy
2,292,567
+357,645
+18% +$9.83M 2.05% 16
2023
Q4 		$57.1M Buy
1,934,922
+500,000
+35% +$15.1M 2.28% 17
2023
Q3 		$45.3M Buy
1,434,922
+170,000
+13% +$4.66M 1.83% 16
2023
Q2 		$32.7M Buy
1,264,922
+530,000
+72% +$14.1M 1.55% 19
2023
Q1 		$17.7M Buy
734,922
+357,548
+95% +$8.15M 1.1% 18
2022
Q4 		$7.36M Sell
377,374
-987,412
-72% -$19.5M 0.53% 21
2022
Q3 		$28.7M Sell
1,364,786
-21,211
-2% -$511K 1.68% 16
2022
Q2 		$27M Buy
1,385,997
+640,997
+86% +$15.1M 1.82% 17
2022
Q1 		$16.4M Buy
+745,000
New +$15.2M 0.82% 18

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cadian Capital Management's MIRM Position: Q4 2024 in Review

Cadian Capital Management sold out of Mirum Pharmaceuticals (MIRM) in Q4 2024, closing a stake of 475,714 shares — an estimated $18.6M sold.

Cadian Capital Management first reported a position in MIRM in Q1 2022 and held it in 11 quarters. The position peaked at $57.6M in Q1 2024. 205 funds tracked by Wall St. Rank hold MIRM as of Q4 2024.

  • Cadian Capital Management reported no remaining Mirum Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Cadian Capital Management sold 475,714 Mirum Pharmaceuticals shares in Q4 2024, an estimated $18.6M.
  • Cadian Capital Management first reported a position in Mirum Pharmaceuticals in Q1 2022 and held it in 11 quarters.
  • Cadian Capital Management's Mirum Pharmaceuticals position peaked at $57.6M in Q1 2024.
  • 205 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2024.

Based on Cadian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.